ALK’s (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the company’s 2023 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook. ALK expects to continue its growth trajectory and earnings improvement in 2024.
(Revenue and earnings growth rates are stated in local currencies. Comparative figures for 2022 are shown in brackets.)
Q4 2023 financial highlights
- Revenue increased by 10% to
DKK 1,345 million (1,249) with growth in all sales regions. - Tablet sales increased by 19% to
DKK 677 million (581), while SCIT/SLIT-drops sales increased by 3% toDKK 522 million (512). Sales of other products were down 3% toDKK 146 million (156). - EBIT increased to
DKK 194 million (138) on higher sales, improved gross margin and efficiencies.
Growth | Growth | |||||
In DKKm | Q4 2023 | l.c. | r.c. | FY 2023 | l.c. | r.c. |
Revenue | 1,345 | 10% | 8% | 4,824 | 9% | 7% |
EBIT | 194 | 37% | 41% | 666 | 50% | 42% |
EBIT margin – % | 14% | 14% | ||||
l.c.: local currency; r.c.: reported currency |
Full-year 2023 financial highlights
- Revenue increased by 9% to
DKK 4,824 million (4,511) based on growth in all sales regions. Exchange rates impacted reported growth negatively by 2 p.p. - Tablet sales increased by 11% to
DKK 2,296 million (2,102). European tablet sales regained momentum in the second half-year with 13% growth. - Sales of SCIT and SLIT-drops increased by 12% to
DKK 1,939 (1,748), while sales of other products and services decreased 9% toDKK 589 million (661) as supply shortages affected sales of Jext® adrenaline auto-injectors. - EBIT increased by 50% to
DKK 666 million (470), corresponding to a 14% EBIT margin (10) on higher sales, improved gross margin and a lower capacity cost to revenue ratio. - Free cash flow was positive at
DKK 292 million (65).
2024 financial outlook
ALK expects broad-based growth across sales regions and product groups in 2024 with tablet sales being key to growth. Profitability is expected to further improve, driven by revenue growth, benefits of scale and a reduction in external costs for clinical trials.
- Revenue is expected to grow by 9-12% in local currencies.
- The EBIT margin is expected at 17-19% against 14% in 2023.
ALK's CEO
ALK-Abelló A/S
The comprehensive annual report continues on the subsequent pages.
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media:
Webcast
Today, ALK is hosting a conference call for analysts and investors at
To register for the conference call, please use this link https://dpregister.com/sreg/10185513/fb5a5565cd and follow the registration instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm,
Attachments
- ALK_AR-2023_appron
- alk-2023-12-31-en
Source: ALK Abello
2024 GlobeNewswire, Inc., source